Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070291 · ClinicalTrials.gov registry record · Phase 2
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00070291 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 4 participants.
The verdict
NCT00070291, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.
Interventions
- DRUG cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-01-24 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070291
The ClinicalTrials.gov registry entry for NCT00070291 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cyclosporine is the first listed.
NCT00070291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070291 about?
NCT00070291 is a clinical study titled "Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma". RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.
What is the current status of trial NCT00070291?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-01-24. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00070291?
The interventions under investigation include: cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00070291?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.